This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Collette, L. Articles by Schröder, F. H. Search for Related Content PubMed PubMed Citation Articles by Collette, L. Articles by Schröder, F. H. Social Bookmarking                            What's this?

Is Prostate-Specific Antigen a Valid Surrogate End Point for Survival in Hormonally Treated Patients With Metastatic Prostate Cancer? Joint Research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals

From the European Organisation for Research and Treatment of Cancer Data Center, Brussels; Limburgs Universitair Centrum, Diepenbeek, Belgium; AstraZeneca Pharmaceuticals, Macclesfield, United Kingdom; and Erasmus Medical Centrum, Rotterdam, the Netherlands

Address reprint requests to Laurence Collette, MSc, European Organization for Research and Treatment of Cancer Data Center, Avenue Emmanuel Mounier 83/11, B-1200 Brussels, Belgium; e-mail: laurence.collette{at}eortc.be

PURPOSE: The long duration of phase III clinical trials of overall survival (OS) slows down the treatment-development process. It could be shortened by using surrogate end points. Prostate-specific antigen (PSA) is the most studied biomarker in prostate cancer (PCa). This study attempts to validate PSA end points as surrogates for OS in advanced PCa.

PATIENTS AND METHODS: Individual data from 2,161 advanced PCa patients treated in studies comparing bicalutamide to castration were used in a meta-analytic approach to surrogate end-point validation. PSA response, PSA normalization, time to PSA progression, and longitudinal PSA measurements were considered.

RESULTS: The known association between PSA and OS at the individual patient level was confirmed. The association between the effect of intervention on any PSA end point and on OS was generally low (determination coefficient, < 0.69).

CONCLUSION: It is a common misconception that high correlation between biomarkers and true end point justify the use of the former as surrogates. To statistically validate surrogate end points, a high correlation between the treatment effects on the surrogate and true end point needs to be established across groups of patients treated with two alternative interventions. The levels of association observed in this study indicate that the effect of hormonal treatment on OS cannot be predicted with a high degree of precision from observed treatment effects on PSA end points, and thus statistical validity is unproven. In practice, non-null treatment effects on OS can be predicted only from precisely estimated large effects on time to PSA progression (TTPP; hazard ratio, < 0.50).

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. de Crevoisier, K. Slimane, T. Messai, P. Wibault, F. Eschwege, A. Bossi, S. Koscielny, A. Bridier, C. Massard, and K. Fizazi Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy Ann. Onc., October 13, 2009; (2009) mdp365v1. [Abstract] [Full Text] [PDF]

				D. Olmos, H.-T. Arkenau, J. E. Ang, I. Ledaki, G. Attard, C. P. Carden, A. H. M. Reid, R. A'Hern, P. C. Fong, N. B. Oomen, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience Ann. Onc., January 1, 2009; 20(1): 27 - 33. [Abstract] [Full Text] [PDF]

				J. S. de Bono, H. I. Scher, R. B. Montgomery, C. Parker, M. C. Miller, H. Tissing, G. V. Doyle, L. W.W.M. Terstappen, K. J. Pienta, and D. Raghavan Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer Clin. Cancer Res., October 1, 2008; 14(19): 6302 - 6309. [Abstract] [Full Text] [PDF]

				R. Thuret, C. Massard, M. Gross-Goupil, B. Escudier, M. Di Palma, A. Bossi, R. de Crevoisier, A. Chauchereau, and K. Fizazi The postchemotherapy PSA surge syndrome Ann. Onc., July 1, 2008; 19(7): 1308 - 1311. [Abstract] [Full Text] [PDF]

				L. Collette, M. Buyse, and T. Burzykowski Are Prostate-Specific Antigen Changes Valid Surrogates for Survival in Hormone-Refractory Prostate Cancer? A Meta-Analysis Is Needed! J. Clin. Oncol., December 10, 2007; 25(35): 5673 - 5674. [Full Text] [PDF]

				M. Gross, I. Top, I. Laux, J. Katz, J. Curran, C. Tindell, and D. Agus {beta}-2-Microglobulin Is an Androgen-Regulated Secreted Protein Elevated in Serum of Patients with Advanced Prostate Cancer Clin. Cancer Res., April 1, 2007; 13(7): 1979 - 1986. [Abstract] [Full Text] [PDF]

				F. H Schroder Early versus delayed endocrine therapy for prostate cancer Endocr. Relat. Cancer, March 1, 2007; 14(1): 1 - 11. [Abstract] [Full Text] [PDF]

				M. Hussain, C. M. Tangen, C. Higano, P. F. Schelhammer, J. Faulkner, E. D. Crawford, G. Wilding, A. Akdas, E. J. Small, B. Donnelly, et al. Absolute Prostate-Specific Antigen Value After Androgen Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data From Southwest Oncology Group Trial 9346 (INT-0162) J. Clin. Oncol., August 20, 2006; 24(24): 3984 - 3990. [Abstract] [Full Text] [PDF]